Tuesday, August 31, 2021

KRISPY KREME® Makes Market Entry into Egypt with First Shop in Cairo

 Franchise partner Americana Group’s opening of Cairo shop expand Krispy Kreme’s effort to provide awesome, fresh doughnuts around the world



CHARLOTTE, N.C.-Tuesday 31 August 2021 [ AETOS Wire ]


(BUSINESS WIRE) -- “Sweet” dreams have become reality in Cairo, Egypt, as Krispy Kreme has opened the global doughnut brand’s first location in the country with its franchise partner Americana Group.


Krispy Kreme’s iconic Hot Light is now beaming in Cairo, signaling to guests that delicious, hot Original Glazed® doughnuts are available to enjoy fresh off the line. The Hot Light Theater shop, which can produce over 100 dozen doughnuts per hour, will be a destination for residents and visitors, while simultaneously serving as a production hub in Krispy Kreme’s omni-channel strategy to distribute and deliver fresh doughnuts daily to customers via multiple points of access.


“The world continues to crave Krispy Kreme, and we continue expanding in a disciplined manner to feed and fuel that craving, growing our business and enhancing lives through the joy that is Krispy Kreme,” said Mike Tattersfield, CEO of Krispy Kreme. “We’re thrilled to serve awesome, fresh doughnuts in Egypt with Americana, our valued franchise partner in the region.”


Americana, an independently owned and operated franchise partner of Krispy Kreme, currently operates more than 200 Krispy Kreme shops in five countries, including UAE, KSA, and Kuwait, and has partnered with Krispy Kreme to delight customers since 2007.


With the shop’s opening on Aug. 19 in New Cairo’s Arabella Plaza, Egypt became the 31st country where fans can enjoy Krispy Kreme doughnuts.


“The joy and love shown for Krispy Kreme by people in Cairo has been truly overwhelming. Our team in Cairo is committed to serving the freshest and tastiest doughnuts on the planet to the millions of Krispy Kreme lovers there. We will continue to open more new outlets as part of our expansion plans in Egypt, bringing Krispy Kreme’s sweet treats to many more happy customers in the coming months,” said Amarpal Sandhu, CEO of Americana Restaurants, an independently owned and operated franchise partner of Krispy Kreme.


“We continue to invest in our global business – driving growth in our existing markets and expanding selectively where we see the kind of great opportunities that we do in Egypt. While we are still in the early days, we already see the benefits of this investment in expanding our omni-channel model as our international business continues to drive strong performance,” added Tattersfield.


About Krispy Kreme


Headquartered in Charlotte, N.C., Krispy Kreme is one of the most beloved and well-known sweet treat brands in the world. Our iconic Original Glazed® doughnut is universally recognized for its hot-off-the-line, melt-in-your-mouth experience. Krispy Kreme operates in 31 countries through its unique network of doughnut shops, partnerships with leading retailers, and a rapidly growing e-Commerce and delivery business. Our purpose of touching and enhancing lives through the joy that is Krispy Kreme guides how we operate every day and is reflected in the love we have for our people, our communities, and the planet. Connect with Krispy Kreme Doughnuts at www.KrispyKreme.com, or on one of its many social media channels, including www.Facebook.com/KrispyKreme, and www.Twitter.com/KrispyKreme.


About Americana:


Americana Group is one of the largest restaurants, food manufacturing, and distributing companies in MENA and CIS countries. It was founded in Kuwait in 1964 and is comprised of two Divisions. The Group operates 2000 restaurants in 13 markets across the Middle East, North Africa, and CIS, as well as 25 food production sites across the region.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005177/en/


Contacts

Chelsea Michael

Chelsea.Michael@fleishman.com



Permalink : https://www.aetoswire.com/news/krispy-kremereg-makes-market-entry-into-egypt-with-first-shop-in-cairo/en



“The Story of New Finance in China(II)” Dives into Latest Innovative Financial Technologies

 SHANGHAI-Tuesday 31 August 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- "The Story of New Finance in China (II)" is a video series on YouTube that explains the latest innovative technologies and how they affect financial institutions in China. The series goes over a variety of financial technologies (called FinTech, for short) including artificial intelligence (AI), cloud computing, blockchain, robotics, big data, and satellite remote sensing.

“The Story of New Finance in China” was created to share information on the development of China's financial system reform with government leaders, enterprises, institutions, and the public. These videos are also offered as a tool for economies around the world that are seeking financial reform, as well.

These videos explain how innovative FinTech including AI, cloud computing, blockchain, and big data has accelerated the application of contactless transactions, allowed financial institutions throughout China to offer more accessible financial services to small and medium enterprises, and more.

Each video in the series has a unique theme:

Video 1: Artificial Intelligence Boosts New Finance Technology

China's financial institutions are realizing that AI can offer personalized services as well as – or better than – humans can. The first video encompasses FinTech and how it is launching China into the future.

Video 2: SME Loans Use Technology to Innovate Financial Services

WeBank is the first online-only bank in China. WeBank’s SME Loans integrate the ABCDs of financial technology (artificial intelligence, blockchain, cloud computing, and big data) to serve small and medium enterprises.

Video 3: The Emergence of Contactless Loans

With WeBank and innovative FinTech, China can now offer contactless loans – loans that can be applied for and received through the internet. Enterprises that are operating in uncertain environments or have been affected by COVID-19 find this tool to be invaluable.

Video 4: Zheshang Bank Applies Blockchain Innovative Financial Services

Zheshang Bank uses blockchain technology and the Internet of Things (IoT) to protect financial and personal data that is shared among platforms.

Video 5: Small and Medium Enterprises in Zhejiang Province, China No Longer Have Difficulty in Financing

Zhejiang Province's financial service platform has improved the quality, accessibility, and efficiency of financial services to small and medium enterprise owners.

To watch the second season of “The Story of New Finance in China”, please visit on YouTube.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005376/en/

Contacts
Chuang Ling
TEL:+86-21-6139-8088
info_cn@linguitronics.com



Permalink : https://www.aetoswire.com/news/ldhe-story-of-new-finance-in-chinaiirdquo-dives-into-latest-innovative-financial-technologies/en


Premium Vape Brand RELX Launches in Kingdom of Saudi Arabia

 • RELX is a premium vaping brand committed to a world without cigarettes


• Steeped in science, technology and design, RELX provides adult smokers and vapers with next generation e-cigarette products


RIYADH, Saudi Arabia-Monday 30 August 2021 [ AETOS Wire ]


(BUSINESS WIRE) -- RELX, a premium vaping brand at the forefront of the e-cigarette evolution has now launched in the Kingdom of Saudi Arabia. The e-cigarette brand is already available in the United Arab Emirates and Kuwait – and has further plans to expand into the wider MENA region this year.


The Kingdom has announced new regulations, similar to those set across Europe, following the standard set up for e-cigarette packaging and labeling which was introduced in September 2020.


What sets RELX International apart from other e-cigarette brands is its innovation, design and quality – all of which is underpinned with a strong ethical stance. RELX International conducts its business with integrity, working with its partners to ensure its goods are strictly for adult smokers and vapers only.


RELX International products are designed at a cutting-edge research and development centre with extremely stringent inspection and rigorous quality control processes. It truly understands the needs of its adults consumers, and the products are designed to provide them with exceptional alternatives of the highest quality and the most satisfying user experience possible.


Furthermore, it strictly forbids recommending, marketing or selling e-cigarettes to both non-smokers/ vapers and underage consumers and has numerous initiatives in place to promote youth prevention agenda among stakeholders, commercial and business partners.


Fouad Barakat, KSA General Manager at RELX International, commented on the launch: “The MENA region is one of our category’s fastest growing markets, growing at a rate just short of 10% until 2024. Saudi Arabia is one of the region’s largest and most prosperous markets, hence the need for any brand to launch there if it wants to thrive and grow bigger.”


Founded in 2019, RELX International products are designed at a cutting-edge research and development centre with extremely stringent inspection and rigorous quality control processes. It truly understands the needs of its adult consumers and the products are designed to provide them with exceptional alternatives of the highest quality and the most satisfying user experience possible.


After much research, Bing Du founded RELX International, which is now Asia and China’s leading e-cigarette brand with presence in Asia, the UK, USA, Canada, New Zealand and Indonesia, among many other markets worldwide.


Vaping nicotine is set to replace smoking over the next 10 years and could see 1.6 million premature deaths avoided and 20.8 million quality adjusted years of life saved in the United States alone.1


With wide product offerings based around a consumer centric design, plus a wide flavour pool for different regional preferences, based on market insights, RELX International will also be releasing new seasonal flavours developed on a regular basis.


There are two products available:


RELX Infinity


The brand's hero product, it comes with wireless charging and clicks into place with a built-in pogo pin all without wires. Its charging case slips easily into pockets (it is just 15mm in width) and delivers up to two to three full charges with its dual system in just 45 minutes time.


Engineered to improve a variety of aspects of the vaping experience such as sufficient amounts of vapour, comfortable temperature, optimal mouthfeel and sensitive activation, it is also bolstered with metallic seals, maze-like leak traps and silicone layers and 11 structural layers in total to help prevent e-liquid leakages and condensation.


RELX Nano2


RELX nano2 is a sleek, disposable device which features a user-friendly design. RELX nano offers RELX's quality and technology standards at the lowest price point. This device is perfect if you're a first-time e-cigarette user or if you're looking for a compact and discreet vape pen.


For more information on RELX International please visit https://sa.relxnow.com


Notes to Editors


About RELX International


Founded in 2019, RELX International is a multinational electronic cigarette company that markets and sells RELX, Asia's leading e-cigarette brand. RELX branded products are designed at a cutting-edge research and development center, and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for adult smokers through state-of-the-art products, industry-leading technologies and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Proctor and Gamble, Apple, Beats, and L'OrĂ©al.


Website: www.relxnow.com

Facebook: @RelxArabia

Instagram: @RelxArabia


1 SCIENCE (13 Dec 2019 Vol. 366, Issue 6471) the latest claims that more than 8 million smokers will die prematurely from smoking cigarettes, not from the nicotine itself. Vaping nicotine to replace most smoking over the next 10 years could see 1.6 million premature deaths avoided and 20.8 million quality adjusted years of life saved in the US alone


View source version on businesswire.com: https://www.businesswire.com/news/home/20210829005018/en/


Contacts

Amanda Simpson

relxarabia@wearebrazenpr.com



Permalink : https://www.aetoswire.com/news/premium-vape-brand-relx-launches-in-kingdom-of-saudi-arabia/en


Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines

 ST. GALLEN, Switzerland-Tuesday 31 August 2021 [ AETOS Wire ]

  • 2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose) in patients with HF
  • Periodic screening for iron deficiency and the use of Ferinject® to reduce hospitalisation rates and improve HF symptoms are now recommended
  • In addition, Veltassa®(patiromer) is newly proposed to enable the use of renin-angiotensin aldosterone system inhibitor (RAASi) in patients with hyperkalemia

 

(BUSINESS WIRE-- Regulatory News:

Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa®.

With regard to iron deficiency, the following new recommendations for HF patients with reduced function of the heart are added:

  • Periodic screening for iron deficiency is recommended in all HF patients (Class I).

  • Ferinject® should be considered to reduce the risk of HF hospitalizations in symptomatic HF patients with iron deficiency (Class IIa).

  • Ferinject® should be considered before and early after discharge in patients who have been hospitalized with acute heart failure and with iron deficiency to improve HF symptoms and reduce risk of re-hospitalizations (Class IIa).

The existing recommendation to consider Ferinject® in patients with HF and iron deficiency to alleviate HF symptoms, improve exercise capacity and quality of life remains unchanged (Class IIa designation)The results of the AFFIRM-AHF study are reflected in the update of the ESC guidelines. Ferinject® remains the only intravenous (i.v.) iron therapy specifically mentioned in the new ESC HF guidelines.

The guidelines also propose that the use of potassium binder agents like Veltassa® may allow RAAS inhibitor initiation or uptitration in a larger proportion of heart failure patients. In patients with chronic or recurrent hyperkalemia on RAAS inhibitor therapy Veltassa® may as well be initiated to maintain the patients on guidelines recommended doses of RAAS inhibitors. The new proposals further describe the unique evidence for RAASi enabling generated by Veltassa® through the clinical trials.

“We are very pleased with the new recommendations to the ESC’s guidelines in heart failure and are grateful for this development for the patients,” commented Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “With improved diagnosis rates of iron deficiency and enabling RAASi, more patients can benefit from treatment. Reducing the risk of heart failure hospitalizations and improving symptoms are key therapeutic goals in the treatment of heart failure. We are particularly pleased by the consideration of Ferinject® and Veltassa® in the new treatment guidelines to achieve these therapeutic goals and believe this will enable us to further expand our role in helping heart failure patients with iron deficiency and hyperkalemia live better, healthier lives.”

The ESC HF guidelines aim to provide practical, evidence-based recommendations for the diagnosis and treatment of HF, thereby improving and harmonizing standards of diagnosis and treatment of cardiovascular diseases for physicians, and potentially optimizing patient care. The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021.

The 2021 ESC guidelines are published under: www.escardio.org/Guidelines

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

About AFFIRM-AHF
The AFFIRM-AHF study was a multi-center, randomized, double-blind, placebo-controlled trial, comparing the effect of intravenous ferric carboxymaltose (FCM) on hospitalizations and mortality in iron deficient patients admitted for acute heart failure. The study demonstrated that administration of Ferinject® reduced the risk of HF hospitalizations and improved quality of life with no apparent effect on the risk of cardiovascular death.

About Ferinject®
Ferinject®/Injectafer® (ferric carboxymaltose) is a leading i.v. iron therapy with market authorization in 84 countries by the end of June 2021. More than 16 million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2.

About Veltassa®
Veltassa® (patiromer) is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium. Veltassa® should not replace emergency treatment for life-threatening hyperkalemia.

References:
1 Anker, S.,D. (2018). Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient meta-analysis. Eur J Heart fail. 20(1):125-133. doi: 1002/ejhf.823.
2 Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005519/en/


Contacts

Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73

media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90

investors@viforpharma.com


Permalink : https://www.aetoswire.com/news/vifor-pharmarsquos-ferinjectregnbspgranted-new-recommendations-in-updated-2021-esc-heart-failure-guidelines/en

Masimo SafetyNet Alert™ Launches in Western Europe

 Breakthrough Noninvasive Blood Oxygen Monitoring and Alert System Helps Safeguard Patients Taking Opioids at Home


NEUCHATEL, Switzerland-Monday 30 August 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the CE marking and launch in western Europe of Masimo SafetyNet Alert™, an arterial blood oxygen saturation monitoring and alert system designed for use at home. Masimo SafetyNet Alert features Signal Extraction Technology® wearable fingertip pulse oximetry sensor that communicates wirelessly to an accompanying Home Medical Hub and smartphone app. Masimo SafetyNet Alert monitors blood oxygen saturation (SpO2) and pulse rate (PR) using clinically proven Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry and perfusion index (Pi). The system provides escalating alerts when drops in oxygen levels are detected, designed to wake up the person suffering from opioid overdose and if they do not, to send alerts to others when help may be needed.

Over 200 million people are monitored with Masimo SET® pulse oximetry in hospitals each year.1 In hospitals, continuous Masimo SET® oxygen saturation monitoring has been shown to reduce harm associated with opioids in multiple clinical trials, including a 10-year study in which researchers at Dartmouth-Hitchcock Medical Center found that the use of Masimo SET®-based continuous patient surveillance monitoring resulted in zero opioid-related preventable deaths or brain damage in their post-surgical wards. The researchers also found there was a reduction in rapid rescue events by 60%, a reduction in ICU transfers by 50%, and an estimated $7 million annually in cost savings.2-4

Opioids are powerful painkillers, and are commonly used as part of recovery after surgery and for patients with chronic pain, but they can also slow or stop one’s breathing, potentially leading to heart attack, brain damage, and even death. In 2020 the number of drug-related deaths recorded in England and Wales rose to 4,561, the highest since records began, and around half of these involved opioids.5 Worldwide, that number is even worse, with an estimated more than 100,000 people dying from opioid overdose each year.6 Whether taking prescription or non-prescription opioids, people can suffer from the condition known as opioid-induced respiratory depression (OIRD) to varying degrees.6 Opioid overdose may occur while a person is particularly vulnerable, while asleep, and the risk of opioid overdose-related death is heightened for people taking opioids for the first time, those who have sleep apnea, COPD, or asthma, along with those who combine opioids with alcohol or other sedatives, amongst other factors.6-8 By monitoring a person’s oxygen saturation level, especially while asleep, and providing escalating alerts when help may be needed, Masimo SafetyNet Alert can help identify life-threatening opioid overdose before it causes lasting harm or even death.

Masimo SafetyNet Alert leverages the same SET® pulse oximetry technology and a similar notification escalation policy used in hospitals to bring hospital-proven monitoring to the home setting. The system provides escalating visual and audible alerts on the smartphone app and at the Home Medical Hub station, which are designed to alert the patient or anyone nearby to help prompt action. If oxygen levels continue to decline, designated emergency contacts, such as friends and family members, are also notified via text messages, so that they can intervene or involve Emergency Medical Services as needed.

Masimo SafetyNet Alert brings to the home the breakthrough Masimo SET® pulse oximetry used in hospitals around the world. SET® has been clinically proven to help care teams enhance patient safety and improve patient outcomes; in fact, more than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies during motion and low perfusion conditions, providing clinicians with increased sensitivity and specificity to make critical care decisions.9

Dr. Mike Durkin, a Senior NHS Advisor on Patient Safety Policy and Leadership for the National Institute for Health Research (NIHR) Imperial College Patient Safety Translational Research Centre, said, “Patients recovering from surgery still need pain relief using opioid drugs after they are discharged from hospital and return home. However, these drugs have significant side-effects, particularly on the depression of breathing, which without urgent intervention can result in serious harm or death. The technology is now available to monitor the impact of opioids on breathing and it is vital that patients are given the opportunity to easily and continuously monitor their oxygen levels and vital signs while taking these medications at home. This will greatly improve the safety of patients while rehabilitating at home.”

Yvonne Gardner, mother of 21-year-old Parker Stewart, who died of an opioid overdose after taking only half of the prescribed dose of painkillers following a tonsillectomy, said, “I’ve had so many people call me personally and say, what would you do differently? My son needs a tonsillectomy, or my daughter is going into surgery. I tell them: make sure your doctor gives you a monitor.”

Joe Kiani, Founder and CEO of Masimo, said, “30 years ago, we had the dream of improving patient outcomes and reducing the cost of care by taking noninvasive monitoring to new sites and applications. Bringing our measure-through motion and low perfusion pulse oximetry to the home to monitor patients taking opioids is fulfilling that dream in a way that I could not have imagined at the time. I hope tens of thousands of lives will be saved each year from opioid overdose with the launch of Masimo SafetyNet Alert.”

Masimo SafetyNet Alert has not received FDA 510(k) clearance and is not available for sale in the United States.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.9 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,10 improve CCHD screening in newborns,11 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.2-4,12 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,1 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22 U.S. News and World Report Best Hospitals Honor Roll.13 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView®, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

    Estimate: Masimo data on file.

    Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.

    McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.

    McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.

    Office for National Statistics. (2021) Deaths related to drug poisoning in England and Wales: 2020 registrations. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2020. Last accessed August 2021.

    Opioid Overdose. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/opioid-overdose.

    Gupta K et al. Curr Opin Anaesthesiol. 2018;31(1):110-119.

    Subramani Y et al. Br J Anaesth. 2017;119(5):885-899.

    Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.

    Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

    de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.

    Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.

    http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SafetyNet Alert™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SafetyNet Alert, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210829005026/en/

Contacts

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

Permalink : https://www.aetoswire.com/news/masimo-safetynet-alerttrade-launches-in-western-europe/en

Kava & Chai first to reopen at American University of Sharjah with students’ return

 Sharjah, United Arab Emirates-Sunday 29 August 2021 [ AETOS Wire ]


Kava & Chai, the UAE homegrown coffee and tea house, was the first to re-open its outlet today at the American University of Sharjah as students return for the forthcoming academic year.


Exciting times lie ahead for new students and returnees alike as the celebrated Kava & Chai outlet will once again be at their disposal. AUS students can even skip the queue and take advantage of a new online ordering system as well as a variety of special offers.


Students have lots to look forward to as the new term approaches. Since its opening, Kava & Chai has been the go-to place for students and staff at the university, whether for meetings or simply to catch up with friends. There is a feeling of enthusiasm and renewed confidence in the air as the COVID-19 vaccine roll-out continues apace, creating a sense of normality for the year ahead.


Being the first of its outlets to open in the UAE, Kava & Chai at AUS holds a special place in the hearts of coffee drinkers, as it seeks to recreate traditional Middle Eastern tastes whilst using the most fragrant ingredients and modern techniques.


Mike Butler, CEO of Kava & Chai said: “We are seeing a very solid recovery in the market and are excited to reconnect with specialty coffee and tea lovers on campus. Our cafĂ© at AUS fosters a sense of community where traditional ideas fuse with modern interpretation”.


Kava & Chai staff members have been fully vaccinated and have undertaken rigorous training to ensure that appropriate hygiene standards are met. Special disposable yet 100% compostable cups not only contribute to environmental preservation and save on the washing up, but also allow customers an additional safety guarantee.


The first coffee houses are believed to have originated in Syria before spreading to the Arabian Peninsula and later to Turkey, by the 16th century. These became social hubs where people played board games, listened to stories and discussed the news of the day. Everyone was welcome. Differing views were exchanged, cultures mingled, all whilst enjoying a freshly prepared cup of coffee.  The Kava & Chai philosophy is to continue the original coffee house concept. Great pride is taken in the quality of the coffee and tea and in making sure that there is something there for everyone. New flavours, such as the Kava and Chai frappe, a subtle combination of coffee and tea or their signature blend, Vimto Colada, a fusion of tropical flavours, are welcome additions to the menu.


Kava & Chai, a subsidiary of Crescent Enterprises, currently operates five outlets across Dubai, as well as its outlet at the AUS in Sharjah. These can be found at DIFC, Mall of the Emirates, Dubai Police Officers’ Club and in the Al Seef District.


Contacts

Omnia Tarek


o.tarek@saharapr.com



Permalink : https://www.aetoswire.com/news/kava-amp-chai-first-to-reopen-at-american-university-of-sharjah-with-studentsrsquo-return/en


Monday, August 30, 2021

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

 - In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1

- The benefit in the primary endpoint was independent of ejection fraction or diabetes status1

- Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart failure by 27 percent and significantly slowed kidney function decline1

- Results from the Phase III EMPEROR-Preserved trial were presented today at the European Society of Cardiology Congress 20212 and published in The New England Journal of Medicine1



INGELHEIM, Germany & INDIANAPOLIS-Saturday 28 August 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- Full results from the landmark EMPEROR-Preserved Phase III trial demonstrated that empagliflozin showed an impressive 21 percent relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo.1 The benefit was independent of ejection fraction or diabetes status,1 establishing empagliflozin as the first and only treatment to significantly improve outcomes for the full spectrum of heart failure patients. The results were presented today at the European Society of Cardiology (ESC) Congress 20212 and published in The New England Journal of Medicine,1 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

Key secondary endpoint analyses from the trial showed that empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart failure by 27 percent and significantly slowed kidney function decline.1

“For people with heart failure with preserved ejection fraction, the reality is that so far there are no clinically proven treatments we can offer that would make a significant impact on their condition,” said Professor Stefan Anker, EMPEROR-Preserved Principal Investigator and Heart Failure Cardiologist at CharitĂ© Berlin, Germany. “This data brings hope for millions of patients suffering from heart failure with a preserved ejection fraction. The primary endpoint was similarly improved in all subgroups of patients, in men and women, with and without diabetes, and regardless of their ejection fraction and kidney function level. This underlines the breadth of empagliflozin’s efficacy and its potential overall impact.”

More than 60 million people worldwide have heart failure and approximately half of them have HFpEF, which is also known as diastolic heart failure.3,4 HFpEF has been described as the single largest unmet need in cardiovascular medicine based on prevalence, poor outcomes and the absence of clinically proven therapies to date.5,6

EMPEROR-Preserved included 5,988 people with heart failure.1 Of these, 4,005 had a left ventricular ejection fraction (LVEF) of 50 percent or above and 1,983 had a LVEF below 50 percent.1 Trial participants were randomly assigned to empagliflozin 10 mg (n=2,997) or placebo (n=2,991) once daily.1 The overall safety data was consistent with previous findings, confirming the well-established safety profile of empagliflozin.7

“Heart failure is a complex, serious health issue and a leading cause of hospitalization,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “The risk of death in people with heart failure rises with each hospital admission and with kidney function decline. The landmark EMPEROR-Preserved trial shows that empagliflozin brings significant benefit, which is incredibly exciting and welcome news for both the medical and patient communities.”

“These impressive results will bring hope for the millions of people who currently have limited therapeutic options for a very serious, life-threatening condition,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. “Now there is a light at the end of the tunnel. If approved, empagliflozin would become the first clinically proven therapy across the full heart failure spectrum. The results of EMPEROR-Preserved offer an opportunity to fundamentally change the future for people with heart failure.”

The benefits demonstrated in the EMPEROR-Preserved trial are similar to those in the EMPEROR-Reduced trial, in which empagliflozin significantly reduced the relative risk of the composite endpoint of cardiovascular death or hospitalization for heart failure by 25 percent, compared with placebo, in adults with heart failure with reduced ejection fraction (HFrEF).8 Together, these studies demonstrate the benefits of empagliflozin for patients across the full heart failure spectrum.

Empagliflozin is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes.9,10,11 Additionally, empagliflozin is approved for the treatment of adults with HFrEF in the European Union and the U.S.9,12 Boehringer Ingelheim and Lilly Alliance plan for global regulatory submissions in HFpEF in 2021. Research is ongoing regarding the effects of empagliflozin on hospitalization for heart failure and mortality in post-myocardial infarction (heart attack) patients with high risk of heart failure.13 Empagliflozin is also currently being investigated in chronic kidney disease.14

 

About the EMPEROR heart failure studies15,16
The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) chronic heart failure studies were two Phase III, randomized, double-blind trials that investigated once-daily empagliflozin compared to placebo in adults with chronic HFrEF or HFpEF, with or without diabetes:

    EMPEROR-Reduced [NCT03057977] investigated the safety and efficacy of empagliflozin in patients with chronic HFrEF.

    Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure

    Number of patients: 3,730

    Completion: 2020

    EMPEROR-Preserved [NCT03057951] investigated the safety and efficacy of empagliflozin in patients with chronic HFpEF.

    Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure

    Number of patients: 5,988

    Completion: 2021

    Link to lay summary

About the EMPOWER program
The Boehringer Ingelheim and Lilly Alliance has developed the EMPOWER program to explore the impact of empagliflozin on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions. Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and account for up to 20 million deaths annually.17 Through the EMPOWER program, the Alliance is working to advance knowledge of these interconnected systems and create care which offers integrated, multi-organ benefits. Comprised of nine clinical trials and two real-world evidence studies, EMPOWER reinforces the long-term commitment of the Alliance to improve outcomes for people living with cardio-renal-metabolic conditions. With more than 400,000 adults enrolled worldwide in clinical studies, it is one of the broadest and most comprehensive clinical programs for an SGLT2 inhibitor to date.

About heart failure
Heart failure is a progressive, debilitating and potentially fatal condition that occurs when the heart cannot supply adequate circulation to meet the body’s demands for oxygenated blood.18 To do so, it requires increased blood volume leading to fluid accumulation (congestion) in the lungs and peripheral tissues.19 It is a common condition affecting over 60 million people worldwide and expected to increase as the population ages.3,4 Heart failure is highly prevalent in people with diabetes;20 however, more than half of all people with heart failure do not have diabetes.21

There are different types of heart failure. People with left-sided heart failure have either a reduced or a preserved ejection fraction. Ejection fraction is a measurement of the percentage of blood the left ventricle pumps out with each contraction.22 When the heart relaxes, the ventricle refills with blood.

    Heart failure with preserved ejection fraction occurs when the left ventricle of the heart is unable to relax and properly fill with blood, resulting in less blood being available to be pumped out to the body.22

    Heart failure with reduced ejection fraction occurs when the left ventricle of the heart is not able to contract effectively, which means that the heart cannot pump with enough force, so less blood is pushed out to the body.22

People with heart failure often experience breathlessness and fatigue, which can severely impact their quality of life.23 Individuals with heart failure often also have impaired kidney function, which can have a significant negative impact on prognosis.24

About cardio-renal-metabolic conditions
Boehringer Ingelheim and Lilly are driven to transform care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.4,17

The cardiovascular, renal and metabolic systems are interconnected, and share many of the same risk factors and pathological pathways along the disease continuum. Dysfunction in one system may accelerate the onset of others, resulting in progression of interconnected diseases such as type 2 diabetes, cardiovascular disease, heart failure, and kidney disease, which in turn leads to an increased risk of cardiovascular death. Conversely, improvements in one system can lead to positive effects throughout the others.25,26,27

Through our research and treatments, our goal is to support people’s health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our commitment to those whose health is jeopardized by cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling treatment gaps.

About empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.9,10,11

Please click on the following link for ‘Notes to Editors’ and ‘References’ https://www.boehringer-ingelheim.com/press-release/emperor-preserved-heart-failure-full-data

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210827005316/en/

Contacts

Stefanie Molkenthin
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 172 209

Anna Bergmann
Global Business Communications
Eli Lilly and Company
Email: anna.bergmann@lilly.com
Phone: +1 317 864 3143


 
Permalink : https://www.aetoswire.com/news/landmark-trial-demonstrates-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction/en

Sunday, August 29, 2021

T-Mobile’s Use of Rimini Street Support for Its SAP Applications Helps Enable Competitive Differentiation and Enhanced Customer Experiences

 Company’s mission-critical, global support infrastructure and advanced technology empowers the fastest and most reliable 5G network provider in the U.S. to deliver on its brand promise


LAS VEGAS-Friday 27 August 2021 [ AETOS Wire ]


(BUSINESS WIRE) -- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that T-Mobile, the fastest and most reliable 5G network provider in the U.S. with an annual revenue of more than $68 billion and over 104 million customers, continues leveraging Rimini Street Support to maximize the return on its SAP enterprise software investments since making the switch to mission-critical, 24/7/365 Rimini Street Support in 2018.


T-Mobile relies on Rimini Street as its trusted partner, receiving the Company’s ultra-responsive, award-winning support for its entire SAP system, including support for the organization’s extensive software customizations which were not covered under the software vendor’s more expensive annual support.


T-Mobile’s SAP platform is comprised of more than 200 SAP modules, is used as the system of record for key financial and operational functions and is a critical component of T-Mobile’s supply chain portfolio – a vital part of the company’s customer experience. Since making the switch from vendor support to Rimini Street, T-Mobile has been able to redirect budget and resources to focus on delivering services and technology aimed at creating competitive differentiation by delighting its customers, rather than wastefully allocating resources to maintaining and managing its SAP infrastructure.


Supply Chain Critical to Customer Engagement and Success


In addition to providing wireless voice and data services, T-Mobile is a leading retailer that sells a variety of phones and devices through retail outlets and is one of the largest and fastest-growing mobile-first banking platforms in the U.S.


In a highly competitive, commoditized mobile phone market, it is critical to deliver the best possible buying experience to each customer, whether online or in-store. The consumer wireless market is dynamic and constantly changing, but the COVID-19 pandemic dramatically changed consumers’ expectations of brands and how they interact with companies moving forward. T-Mobile’s supply chain, which relies on its SAP platform for key operational and financial functions, is foundational to supporting critical aspects of its customers’ journey.


“Most companies ignore the inherent power of their supply chain,” said Erik LaValle, senior director of product and technology for supply chain at T-Mobile. “At T-Mobile, it is a vital part of the customer experience and enables us to deliver on our brand promise. It’s how the commitment to our customers – delivering what they want, when they want and where they want it – really comes to life.”


T-Mobile regularly reviews its vendor portfolio to assess the quality of service and value delivered by its technology vendors. As part of a review of each of its technology providers, the company determined the quality of service they were getting from SAP for support of their mission-critical SAP system, along with the advancement of the technology versus the costs they were paying on an annual basis, were deemed to deliver little ROI or value.


While happy with their SAP system, too much time, money and internal resources were required to support and update the system. In addition, the company had no interest in migrating to a completely new platform – SAP S/4HANA – just to stay fully supported by the vendor, and wanted to continue to leverage its highly-customized system that was meeting its current business needs and expected to meet its needs years into the future, as well as mitigate risk and business disruption in preparation for its merger with Sprint, another large telecom.


“T-Mobile is a very complex environment. When we looked at the service we were getting from SAP versus the value and new functionality offered, it came down to whether or not we were getting a fair exchange from the vendor for support of our mature, highly functional platform,” continued LaValle. “We estimated that SAP only covered about 20% - 30% of our support issues due to our customizations, which meant the cost of each support ticket raised was in the tens of thousands of dollars.”


After learning about and assessing Rimini Street and its high value, cost-effective support model which includes support for customizations and seasoned engineers and technical support the Company assigns to every client, T-Mobile decided to switch their SAP support to Rimini Street. This enabled T-Mobile to extend the life of their SAP investment and redeploy internal IT resources and annual savings to other more strategic customer experience initiatives.


“It became very clear that moving to Rimini Street Support offered a more compelling alternative for us. Throughout our engagement with the company, they have had the right team, in the right place, at the right time. The initial transition, procedures and proven support model ensured a smooth start-up. Everything they did focused on ensuring a transition to a working model that hit the ground running. Only Rimini Street provides the breadth and depth of experience, scalable support infrastructure and advanced technology and processes needed to enhance business continuity and mitigation of financial and operational exposure for an organization of our size and scale,” said LaValle.


24/7/365 Access to a Team of SAP Experts


As with all Rimini Street clients, T-Mobile has an assigned Primary Support Engineer, backed by a team of technical experts with an average of 20+ years’ experience in SAP software. Clients also benefit from the Company’s industry-leading service level agreement of 10-minute response times for critical Priority 1 cases and 15-minute response times for Priority 2 issues, in addition to higher-level discussions on strategy surrounding the client’s technology roadmap.


“Rimini Street does a great job of balancing between tactical delivery and being a strategic partner,” concluded LaValle. “We have great conversations on a regular basis about the future of the technology, the best way to approach our future IT roadmap and how we can balance between our internal delivery and the services Rimini Street provides to advance our team along with the technology. Rimini Street is one of our most trusted IT partners.”


“In today’s environment, every customer interaction is an opportunity to deliver value through exceptional service, and T-Mobile’s Un-carrier moves and supply chain optimization are examples of strategic programs that enhance the buying experience,” said Seth A. Ravin, Rimini Street CEO and chairman of the board. “As a trusted partner to T-Mobile and our enterprise clients around the world, our focus is on delivering the service model, technical expertise and mission-critical responsiveness that enables our clients to maximize their ROI on their enterprise software investments, realize efficiencies and free up resources to focus on more strategic initiatives within their business. We continue to innovate, expand our capabilities and scale our unique portfolio of integrated services to meet the evolving needs of our clients.”


To learn more about T-Mobile’s story, click here.


About Rimini Street, Inc.


Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,200 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.


Forward-Looking Statements


Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the impact of our credit facility’s ongoing debt service obligations and financial covenants and operational covenants on our business and related interest rate risk, the duration of and operational and financial impacts on our business of the COVID-19 pandemic and related economic impact, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; including under our new credit facility; our ability to maintain an effective system of internal control over financial reporting, and our ability to remediate identified material weaknesses in our internal controls, including in relation to the accounting treatment of our warrants; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 4, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.


© 2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005023/en/


Contacts

Michelle McGlocklin

Rimini Street, Inc.

+1 925 523-8414

mmcglocklin@riministreet.com


Permalink : https://www.aetoswire.com/news/t-mobilersquos-use-of-rimini-street-support-for-its-sap-applications-helps-enable-competitive-differentiation-and-enhanced-customer-experiences/en


P&G Studios and Harder Than You Think Foster Game Changing Conversations in New Podcast Series “Equal Too: Achieving Disability Equality”

 The team behind the critically acclaimed Rising Phoenix documentary enlist host and executive producer Sophie Morgan and executive producer SinĂ©ad Burke to spotlight breakthrough conversations about the issues most important to the disabled community



CINCINNATI-Saturday 28 August 2021 [ AETOS Wire ]


(BUSINESS WIRE) -- Today, P&G Studios and the team at Harder Than You Think launch a new podcast series, “Equal Too: Achieving Disability Equality,” to shine a light on the biggest challenges faced by the disabled community and start a conversation about what is needed to drive equality. The podcast, hosted by UK television presenter and disability advocate Sophie Morgan, will focus on challenging perceptions, celebrating successes, and exploring how to transform the world for those who do and do not have a disability. Sophie will speak with some of the most informed and most famous professionals, influencers, and activists about key themes of disability and inclusion.


“Equal Too” is a special six-part series featured on the podcast Seneca’s Conversations on Power and Purpose and is brought to you by the Seneca Women Podcast Network and iHeart Radio. The series will run through August and September and will explore thought-provoking topics, like:


The legacy of the Paralympic Movement and the lasting impact hosting the Paralympic Games has had on host cities and beyond


How legislation for disabled people is changing and what more needs to be done


The path of employment for disabled people 70 years after Sir Ludwig Guttmann began using sport to create space for disabled people in society


For “Equal Too,” the talented team behind the award-winning Netflix documentary Rising Phoenix have brought together an abundance of voices who are policymakers, activists, athletes, and allies from across the globe, including:


Jameela Jamil, actor and host recognized as an advocate for disability rights, LGBTQ+ rights, body neutrality, and her work as founder of the I Weigh Community


RJ Mitte, an American actor, advocate, and philanthropist who has been a global champion in speaking of his experiences with Cerebral Palsy in hopes of removing the stigma associated with disabilities


Tatyana McFadden, a Russian-American athlete who holds 17 Paralympic medals, whose efforts to advocate for disability equality led to the passage of several pieces of legislation to ensure students with disabilities have equal access to compete in athletics


Andrew Parsons, a Brazilian sports administrator, and the president of the International Paralympic Committee (IPC). The IPC and the International Disability Alliance recently spearheaded the launch of the #WeThe15 campaign, a global movement to represent the 1.2 billion people with disabilities in the world


“With ‘Equal Too’ bringing together so many powerful and influential voices, it will help us to work out where the Rising Phoenix story needs to go next,” said Greg Nugent, co-founder of Harder Than You Think and creator of Rising Phoenix. “The threads to the conversation are extraordinary and important and the need for the story to be told is more vital than ever.”


As the world turns its focus to the incredible athletes competing in the Paralympic Games and inspired by the recent launch of the IPC’s #WeThe15 initiative, the biggest disability equality movement of its kind, P&G is committing a $100,000 donation to the Agitos Foundation. This will help fuel the work of the IPC to change how young people perceive those with a disability.


“We believe that greater visibility is a critical step to changing perceptions on the journey to disability equality,” said Phil Duncan, P&G’s Chief Design Officer and Olympic Games Executive. “We all have more to learn, which is why it’s important for us to spotlight the hugely important conversations in ‘Equal Too.’ We are also proud to make a monetary donation to the Agitos Foundation, which is doing incredibly impactful work in raising long lasting awareness for the next generation.”


As meaningful conversations about inclusivity can only be made possible when equal voices are represented, “Equal Too” is made possible by a team – from producers to guests and contributors – comprised of more than 60% of people who identify as disabled. At the helm of the project are two influential women: host and executive producer Sophie Morgan and executive producer and story consultant SinĂ©ad Burke. Sophie, who was paralyzed in a car crash when she was 18, is an award-winning broadcaster who has presented for Channel 4 at every Paralympic Games since the Paralympic Games London 2012 and is one of the first and only female, disabled television hosts in the world. SinĂ©ad, the founder of accessibility consultancy, Tilting the Lens, is a little person who campaigns to raise the baseline standards of accessibility to build a world that is designed with disabled people, for the inclusion of all.


All episodes of the podcast will be released with downloadable transcripts available shortly thereafter. Additionally, they will be accompanied with captioned videos featuring a deaf British Sign Language signer, Rinkoo Barpaga. You can download and listen to “Equal Too,” part of Seneca's Conversations, on the iHeartradio App, Apple Podcasts, or whichever podcast player you use.


About Procter & Gamble


P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.


About P&G Studios


P&G Studios develops and produces stories to help create positive change in society, often shining the light on under-represented voices and acts of good. Like-minded, mission-based creative innovators and innovative NGO organizations partner with P&G Studios to meet the growing demand for authentic stories that uplift and inspire. Recent programs include The Queen Collective and 8:46 films, the National Geographic ACTIVATE Series, The Tent Mender documentary series, TIME 100 Most Influential People of the Year and TIME Person of the Year one-hour specials, Coded short documentary, and the launch of the Seneca Women’s Podcast Network.


About Harder Than You Think


Harder Than You Think is an independent production company whose purpose is to help change the way we think using the power of the story. Harder Than You Think was created and co-founded by Greg Nugent and Godric Smith, formerly Directors of the London 2012 Olympics and Paralympics. Greg and Godric’s work includes the creation of the Heads Together Campaign for Their Royal Highnesses using film, which went on to transform the views of the nation on mental health, and the creation of The Earthshot Prize, which has become the most important award on the plant for action on the environment.


Rising Phoenix is a ten-year mission by Harder Than You Think that aims to change the way the world thinks about human potential. The project was born out of the success of Harder Than You Think's debut film ‘Rising Phoenix,’ a landmark and double Emmy winning feature documentary about the history of the Paralympic Movement released in 2020 on Netflix, and via further films and audio projects in development to tell the story of the next decade.


About Seneca Women


Co-founded by Ambassador Melanne Verveer, the first U.S. Ambassador for Global Women’s Issues, and Kim Azzarelli, a corporate, philanthropic and legal advisor, who together co-authored the best-selling book Fast Forward: How Women Can Achieve Power and Purpose, and joined by Sharon Bowen, former Commissioner of the U.S. Commodity Futures Trading Commission, Seneca Women has sought to accelerate women’s progress through signature thought leadership events at Davos, the Metropolitan Museum of Art and the New York Stock Exchange, as well as through the Seneca Women app, a weekly newsletter, and significant partnerships with the public and private sectors. The Seneca Women Podcast Network provides a platform for the voices of women as well as inspiring, purpose-driven and inclusive content.


About iHeartMedia


iHeartMedia (NASDAQ: IHRT) is the number one audio company in the United States, reaching nine out of 10 Americans every month – and with its quarter of a billion monthly listeners, has a greater reach than any other media company in the U.S. The company’s leadership position in audio extends across multiple platforms, including more than 850 live broadcast stations in over 160 markets nationwide; through its iHeartRadio digital service available across more than 250 platforms and 2,000 devices; through its influencers; social; branded iconic live music events; other digital products and newsletters; and podcasts as the #1 commercial podcast publisher. iHeartMedia also leads the audio industry in analytics, targeting and attribution for its marketing partners with its SmartAudio product, using data from its massive consumer base.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005660/en/


Contacts

Samantha Policano, MMK+

(202) 835-9495

samantha.policano@ketchum.com



Permalink : https://www.aetoswire.com/news/pampg-studios-and-harder-than-you-think-foster-game-changing-conversations-in-new-podcast-series-ldquoequal-too-achieving-disability-equalityrdquo/en


Saturday, August 28, 2021

Analog Devices Completes Acquisition of Maxim Integrated

 WILMINGTON, Mass.-Friday 27 August 2021 [ AETOS Wire ]


(BUSINESS WIRE) -- Analog Devices, Inc. (NASDAQ: ADI) today announced the completion of its previously announced acquisition of Maxim Integrated Products, Inc. (NASDAQ: MXIM). The combination further strengthens ADI’s position as a high-performance analog semiconductor company with trailing twelve-month revenue of over $9 billion1, industry leading margins, and free cash flow of over $3 billion1 on a pro forma basis.


“Today is a tremendous milestone for ADI and I’m delighted to welcome the Maxim team, who share our passion for solving our customers’ most complex technology problems,” said Vincent Roche, President and CEO. “With more than 10,000 engineers and the increased breadth and depth of our best-in-class technologies, we are well-positioned to develop even more complete, cutting-edge solutions for our customers. Together, we will drive the next waves of analog semiconductor innovation, while engineering a healthier, safer and more sustainable future for all.”


Under the terms of the definitive agreement, Maxim stockholders received 0.63 of a share of ADI common stock for each share of Maxim common stock. Maxim common stock will no longer be listed for trading on the NASDAQ stock market.


Combined Board of Directors


In connection with the closing of the transaction, Tunç Doluca, former President and Chief Executive Officer of Maxim, and Mercedes Johnson, former Founding Executive of Avago Technologies, will join the ADI Board of Directors. Mr. Doluca and Ms. Johnson served on Maxim’s Board of Directors until the closing of the transaction.


Special Investor Conference Call and Webcast


ADI plans to host a webcast to discuss its upcoming capital allocation priorities and the updated fourth quarter fiscal 2021 outlook. The webcast is scheduled to begin at approximately 8:30 a.m. Eastern Time on September 8th, 2021 with Vincent Roche, President and Chief Executive Officer, Prashanth Mahendra-Rajah, Senior Vice President, Finance and Chief Financial Officer, and Michael Lucarelli, Senior Director of Investor Relations.


The webcast and accompanying presentation may be accessed live on the internet on Analog Devices’ Investor Relations website at investor.analog.com, or by telephone as follows:


Participant Dial-In (domestic & international): (833) 423-0297

International Participant Passcode: 8334230297

*no passcode required for domestic dial-in


A replay of the conference call will be available approximately two hours after the call concludes and may be accessed for up to two weeks, by dialing 855-859-2056 and entering the conference ID: 7115409.


Both the press release and archived version of the webcast will be available at investor.analog.com.


About Analog Devices


Analog Devices, Inc. (NASDAQ: ADI) operates at the center of the modern digital economy, converting real-world phenomena into actionable insight with its comprehensive suite of analog and mixed signal, power management, radio frequency (RF), and digital and sensor technologies. ADI serves 125,000 customers worldwide with more than 75,000 products in the industrial, communications, automotive, and consumer markets. ADI is headquartered in Wilmington, MA. Visit http://www.analog.com.


Forward-Looking Statements


This communication contains “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements address a variety of subjects, including, for example, statements as to the anticipated benefits of the transaction, the anticipated impact of the transaction on the combined organization’s business and future financial and operating results, and the expected amount and timing of synergies from the transaction. Statements that are not historical facts, including statements about ADI’s beliefs, plans and expectations, are forward-looking statements. Such statements are based on ADI’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “estimate,” “would,” “target” and similar expressions, as well as variations or negatives of these words. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: the uncertainty as to the extent of the duration, scope and impacts of the COVID-19 pandemic; political and economic uncertainty, including any faltering in global economic conditions or the stability of credit and financial markets; erosion of consumer confidence and declines in customer spending; unavailability of raw materials, services, supplies or manufacturing capacity; changes in geographic scope or product or customer mix; changes in export classifications, import and export regulations or duties and tariffs; changes in ADI’s estimate of its expected tax rate based on current tax law; ADI’s ability to successfully integrate Maxim’s businesses and technologies; the risk that the expected benefits and synergies of the transaction and growth prospects of the combined company may not be fully achieved in a timely manner, or at all; adverse results in litigation matters, including the potential for litigation related to the transaction; the risk that ADI will be unable to retain and hire key personnel; unanticipated difficulties or expenditures relating to the transaction, the response of business partners and retention as a result of the transaction; uncertainty as to the long-term value of ADI’s common stock; and the diversion of management time on transaction-related matters. For additional information about other factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to ADI’s and Maxim’s respective periodic reports and other filings with the Securities and Exchange Commission, including the risk factors contained in ADI’s and Maxim’s most recent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain and are made only as of the date hereof. Except as required by law, ADI does not undertake or assume any obligation to update any forward-looking statements, whether as a result of new information or to reflect subsequent events or circumstances or otherwise.


(ADI-WEB)


1 Based on trailing twelve months ending July 31, 2021 for Analog Devices and trailing twelve months ending June 26, 2021 for Maxim. Free cash flow is defined as net cash provided by operating activities, determined in accordance with GAAP, less additions to property, plant and equipment, net.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005486/en/


Contacts

Contacts for ADI


Investor Contact:


Mr. Michael Lucarelli

781-461-3282

investor.relations@analog.com


Media Contact:


Ms. Brittany Stone

917-935-1456

Brittany.Stone@teneo.com




Permalink : https://www.aetoswire.com/news/analog-devices-completes-acquisition-of-maxim-integrated/en